<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34518945</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1364-6753</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Neurogenetics</Title><ISOAbbreviation>Neurogenetics</ISOAbbreviation></Journal><ArticleTitle>FUS mutations dominate TBK1 mutations in FUS/TBK1 double-mutant ALS/FTD pedigrees.</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>65</EndPage><MedlinePgn>59-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10048-021-00671-4</ELocationID><Abstract><AbstractText>Mutations in FUS and TBK1 often cause aggressive early-onset amyotrophic lateral sclerosis (ALS) or a late-onset ALS and/or frontotemporal dementia (FTD) phenotype, respectively. Co-occurrence of mutations in two or more Mendelian ALS/FTD genes has been repeatedly reported. However, little is known how two pathogenic ALS/FTD mutations in the same patient interact to shape the final phenotype. We screened 28 ALS patients with a known FUS mutation by whole-exome sequencing and targeted evaluation for mutations in other known ALS genes followed by genotype-phenotype correlation analysis of FUS/TBK1 double-mutant patients. We report on new and summarize previously published FUS and TBK1 double-mutant ALS/FTD patients and their families. We found that, within a family, mutations in FUS cause ALS while TBK1 single mutations are observed in FTD patients. FUS/TBK1 double mutations manifested as ALS and without a manifest difference regarding age at onset and disease duration when compared to FUS single-mutant individuals. In conclusion, TBK1 and FUS variants do not seem to interact in a simple additive way. Rather, the phenotype of FUS/TBK1 double-mutant patients appears to be dominated by the FUS mutation.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1535-3146</Identifier><AffiliationInfo><Affiliation>Division of Neurodegeneration, Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lattante</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Genomic Medicine, Department of Life Sciences and Public Health, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Medical Genetics, Department of Laboratory and Infectious Disease Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>R&#xfc;stem</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Neurodegeneration, Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knehr</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurodegeneration, Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freischmidt</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Neurodegeneration, Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. jochen.weishaupt@medma.uni-heidelberg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurogenetics</MedlineTA><NlmUniqueID>9709714</NlmUniqueID><ISSNLinking>1364-6745</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C403191">TBK1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">TBK1</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34518945</ArticleId><ArticleId IdType="pmc">PMC8782814</ArticleId><ArticleId IdType="doi">10.1007/s10048-021-00671-4</ArticleId><ArticleId IdType="pii">10.1007/s10048-021-00671-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>White MA, Sreedharan J. Amyotrophic lateral sclerosis. Curr Opin Neurol. 2016;29:557&#x2013;564. doi: 10.1097/WCO.0000000000000367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000367</ArticleId><ArticleId IdType="pubmed">27538057</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Weishaupt JH. Update on amyotrophic lateral sclerosis genetics. Curr Opin Neurol. 2019;32:735&#x2013;739. doi: 10.1097/WCO.0000000000000737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000737</ArticleId><ArticleId IdType="pubmed">31335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Blitterswijk M, Van Es MA, Hennekam EAM, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776&#x2013;3784. doi: 10.1093/hmg/dds199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds199</ArticleId><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34:404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Sieverding K, Bruno C et al (2019) Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J Exp Med jem.20180729. 10.1084/jem.20180729</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V, Kaunga E, Ye J, et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron. 2020;106:789&#x2013;805.e5. doi: 10.1016/j.neuron.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.03.005</ArticleId><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieverding K, Ulmer J, Bruno C et al (2021) Hemizygous deletion of Tbk1 worsens neuromuscular junction pathology in TDP-43G298S transgenic mice. Exp Neurol 335. 10.1016/j.expneurol.2020.113496</Citation><ArticleIdList><ArticleId IdType="pubmed">33038415</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P et al (2018) Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry jnnp-2017-317611. 10.1136/jnnp-2017-317611</Citation><ArticleIdList><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ, Bosco DA, LeClerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (80- ) 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (80- ) 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, Doronzio PN, Marangi G, et al. Coexistence of variants in TBK1 and in other ALS-related genes elucidates an oligogenic model of pathogenesis in sporadic ALS. Neurobiol Aging. 2019;84:239.e9&#x2013;239.e14. doi: 10.1016/j.neurobiolaging.2019.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.03.010</ArticleId><ArticleId IdType="pubmed">31000212</ArticleId></ArticleIdList></Reference><Reference><Citation>de Majo M, Topp SD, Smith BN, et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol Aging. 2018;71:266.e1&#x2013;266.e10. doi: 10.1016/j.neurobiolaging.2018.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.06.015</ArticleId><ArticleId IdType="pmc">PMC6983933</ArticleId><ArticleId IdType="pubmed">30033073</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann M, Peikert K, G&#xfc;nther R, et al. Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2019;6:2384&#x2013;2394. doi: 10.1002/acn3.50930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50930</ArticleId><ArticleId IdType="pmc">PMC6917314</ArticleId><ArticleId IdType="pubmed">31682085</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2014;revised report of an EFNS task force. Eur J Neurol. 2012;19:360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi L, Valenza F, Mosca L, et al. TBK1 mutations in Italian patients with amyotrophic lateral sclerosis: genetic and functional characterization. J Neurol Neurosurg Psychiatry. 2017;88:869&#x2013;875. doi: 10.1136/jnnp-2017-316174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316174</ArticleId><ArticleId IdType="pmc">PMC5629935</ArticleId><ArticleId IdType="pubmed">28822984</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>